Latest Hotspot

AskBio begins Phase 1 trial with first patient for their MSA-P gene therapy, AB-1005

28 November 2023
3 min read

Diary of Bayer AG and independent gene therapy firm, Asklepios BioPharmaceutical, Inc., declared that the Ohio State University Wexner Medical Center has successfully randomized its first patient in the Phase 1 REGENERATE MSA-101 clinical trial. The test concerns AB-1005, a gene therapy that is under development to potentially treat multiple system atrophy-parkinsonian type.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The development of AB-1005 gene therapy, a therapy involving an adeno-associated viral vector that enables the production of glial cell line-derived neurotrophic factor in the putamen, takes a meaningful leap towards potentially benefiting patients. Currently, AB-1005 is also being tested as a possible treatment for mild to moderate Parkinson's disease, with the completion of Phase 1b study participant recruitment.

Several individuals related to the MSA community view the enrollment of the initial participant in the REGENERATE MSA-101, a Phase 1 trial, as a noteworthy occasion, as expressed by Philip M. Fortier, MA, President and Executive Director of the Defeat MSA Alliance.

In his words, "MSA currently has no known cure, nor are there treatments that can halt or slow its progression. This situation is particularly challenging for patients as they often witness a fast deterioration in their condition. The current progress is henceforth seen as a significant step towards potentially altering the prognosis for MSA patients."

MSA-P, often challenging to differentiate from Parkinson's disease, commonly exhibits symptoms like slowed movement, imbalance, unsteady coordination, dizziness, and further difficulties in motor activities. This is primarily caused by a gradual loss of nerve cells in the brain and spinal cord. With an estimated global prevalence of 100,000-500,000, MSA is a rare disease that reportedly appears without an apparent cause. Symptoms generally begin to manifest in patients in their 50s and usually show swift progression within 5-10 years.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, targets, organizations, clinical trials, clinical results, and drug patents related to this indication.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of November 26, 2023, there are 47 investigational drugs for the multiple system atrophy, including 20 targets, 55 R&D institutions involved, with related clinical trials reaching 241, and as many as 12088 patents.

AB-1005 is a gene therapy drug targeting nervous system diseases and endocrinology and metabolic diseases. Its active indications include multiple system atrophy and Parkinson's disease. As the drug is currently in Phase 1 of clinical development, further research and evaluation are needed to determine its safety and efficacy in treating these condition.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

What are COX inhibitors and how do you quickly get the latest development progress?
What are COX inhibitors and how do you quickly get the latest development progress?
24 November 2023
The analysis of the target COX reveals a competitive landscape with several companies making progress in the development of COX inhibitors.
Read →
Medicenna unveils positive survival results from the Phase 2b trial of Bizaxofusp for recurrent Glioblastoma at the 28th annual NeuroOncology Society meeting
Latest Hotspot
3 min read
Medicenna unveils positive survival results from the Phase 2b trial of Bizaxofusp for recurrent Glioblastoma at the 28th annual NeuroOncology Society meeting
24 November 2023
Medicenna reports promising survival gains from the Phase 2b trial of Bizaxofusp for relapsed Glioblastoma, revealed at the 28th yearly NeuroOncology Society gathering.
Read →
EXS-21546: A Quick Look at Its R&D Progress and Clinical Results from the 2023 AACR
EXS-21546: A Quick Look at Its R&D Progress and Clinical Results from the 2023 AACR
24 November 2023
On 14 Apr 2023, data from first-in-human study of EXS21546, an A2A receptor antagonist, was reported at the AACR Congress.
Read →
EBGLYSS® (lebrikizumab) received European Commission approval for treating moderate-to-severe atopic dermatitis
Latest Hotspot
3 min read
EBGLYSS® (lebrikizumab) received European Commission approval for treating moderate-to-severe atopic dermatitis
24 November 2023
EBGLYSS® (lebrikizumab), developed by Almirall, has been given the green light by the European Commission for the treatment of moderate-to-severe atopic dermatitis.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.